Efficacy and safety of pembrolizumab for treating advanced non-small-cell lung cancer: a meta-analysis of phase II and III randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of chemotherapy"
DOI: 10.1080/1120009x.2021.2014714
Abstract: We conducted a meta-analysis to systematically review the efficacy and safety of pembrolizumab for advanced NSCLC. Databases were searched for randomized controlled trials (RCTs) treated with pembrolizumab till July 2021. Seven RCTs and 3988 patients… read more here.
Keywords: efficacy safety; meta analysis; pembrolizumab; randomized controlled ... See more keywords
Safety of pembrolizumab with chemoradiation (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.6011
Abstract: 6011Background: Pembrolizumab (pembro) is a humanized monoclonal antibody that blocks the programmed death receptor-1 (PD-1) interaction with its ligands (PD-L1, PD-L2). While pembro is approved fo... read more here.
Keywords: chemoradiation crt; advanced squamous; locally advanced; safety pembrolizumab ... See more keywords
Review of the Clinical Pharmacokinetics, Efficacy and Safety of Pembrolizumab.
Sign Up to like & getrecommendations! Published in 2022 at "Current drug metabolism"
DOI: 10.2174/1389200223666220609125013
Abstract: BACKGROUND Treatment of various types of cancer has been improved significantly with the discovery of biologic drugs that act as immune checkpoint inhibitors (ICIs). Pembrolizumab is a humanized monoclonal anti-PD-1 antibody currently approved for the… read more here.
Keywords: safety pembrolizumab; efficacy safety; treatment; pembrolizumab ... See more keywords